Deciphera Pharmaceuticals (NASDAQ:DCPH) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Deciphera Pharmaceuticals (NASDAQ:DCPH – Get Rating) posted its quarterly earnings data on Thursday. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.05, Briefing.com reports. Deciphera Pharmaceuticals had a negative net margin of 231.99% and a negative return on equity of 79.39%. The business had revenue of $32.49 million during the quarter, compared to the consensus estimate of $30.11 million. During the same period in the previous year, the firm posted ($1.21) earnings per share. The business’s revenue for the quarter was up 37.8% compared to the same quarter last year.

Deciphera Pharmaceuticals Stock Down 1.8 %

DCPH traded down $0.30 on Friday, reaching $16.51. The stock had a trading volume of 1,277,063 shares, compared to its average volume of 716,774. Deciphera Pharmaceuticals has a 12-month low of $6.51 and a 12-month high of $17.20. The business’s 50-day moving average price is $12.77 and its two-hundred day moving average price is $10.49.

Analyst Ratings Changes

Several equities research analysts have recently commented on DCPH shares. SVB Leerink lifted their price objective on shares of Deciphera Pharmaceuticals from $15.00 to $21.00 and gave the stock an “outperform” rating in a research note on Friday. HC Wainwright raised their target price on shares of Deciphera Pharmaceuticals from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Friday. Finally, JMP Securities raised shares of Deciphera Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $23.00 target price for the company in a report on Friday. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $14.13.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Lazard Asset Management LLC purchased a new position in Deciphera Pharmaceuticals in the first quarter valued at $57,000. Mariner LLC grew its position in shares of Deciphera Pharmaceuticals by 6.6% in the first quarter. Mariner LLC now owns 22,472 shares of the company’s stock valued at $208,000 after purchasing an additional 1,401 shares during the period. MetLife Investment Management LLC grew its position in shares of Deciphera Pharmaceuticals by 55.0% in the first quarter. MetLife Investment Management LLC now owns 23,468 shares of the company’s stock valued at $218,000 after purchasing an additional 8,328 shares during the period. BNP Paribas Arbitrage SA grew its position in shares of Deciphera Pharmaceuticals by 17.0% in the first quarter. BNP Paribas Arbitrage SA now owns 23,557 shares of the company’s stock valued at $218,000 after purchasing an additional 3,417 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Deciphera Pharmaceuticals in the first quarter valued at about $278,000. Hedge funds and other institutional investors own 87.97% of the company’s stock.

About Deciphera Pharmaceuticals

(Get Rating)

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.